News

Pfizer has combined operations with Wyeth following the closing of the acquisition on 15 October, 2009. Pfizer can now offer products in human, animal, and consumer health, including

Toray Industries (Toray) has obtained approval in Japan to add a new indication to its natural-type interferon beta preparation Feron, for the improvement of viraemia in chronic hepatitis

Clinical Center of Serbia, Institute for Cardiovascular Diseases has treated its first patient with a cell-based therapy for heart failure. The patient is participating in an international trial

The FDA has granted marketing approval to Sanofi Aventis, US, for Elitek (rasburicase), for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia,

AstraZeneca and POZEN have submitted a Marketing Authorisation Application (MAA) in the EU via the Decentralised Procedure (DCP) for VIMOVO (enteric-coated naproxen/immediate release esomeprazole magnesium, formerly known as

PIKAMAB has secured exclusive rights to two issued US patents from Hospital for Special Surgery, New York. Reportedly, PIKAMAB is developing Lupus Therasight, a theragnostic product that will

BASF has expanded its application lab for epoxy resin systems at the Ludwigshafen site. Here the company develops new systems and adapts their processing parameters to the specific

KINAXO Biotechnologies and Bayer Vital have entered into collaboration. According to the agreement, KINAXO will apply its phosphoproteomics technology to reveal the drug’s influence on cellular phosphorylation patterns

Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders. Under